Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study.

Innovation (Camb) · 2025 · PMC11763884 · PMID 39872476

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Moreover, somatic mutation of GNAS (p = 0.0565), KMT2D ( p = 0.0565), and TP53 ( p = 0.0854) showed a trend to be correlated with ORR ( Figure 2 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.